Literature DB >> 7406113

Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.

T P Monath, R B Craven, D J Muth, C J Trautt, C H Calisher, S A Fitzgerald.   

Abstract

On the basis of previous studies, it has long been stated that 17D yellow fever (YF) vaccine generally does not induce complement-fixing (CF) antibodies, and that the presence of CF antibodies could be used in epidemiological studies to distinguish individuals infected with wild YF virus from vaccinated persons. In January 1979, seroepidemiological investigations were conducted during a YF epidemic in The Gambia, West Africa. Since a mass vaccination campaign was also in progress, it was important to confirm that the CF test could be used for serodiagnosis and determination of the incidence of natural YF infections. The serological responses of 58 individuals who received 17D YF vaccine were studied. The vaccinees fell into three gorups: 1) those with prevaccination YF neutralizing (N) antibodies; 2) immunological virgins without prevaccination YF-N antibody or hemagglutination-inhibiting (HI) antibodies to heterologous flaviviruses (Zika, West Nile, dengue 1, Uganda S, Spondweni, or Ntaya; and 3) those without prevaccination YF-N antibodies but with heterologous flaviviral HI antibodies. Vaccination of persons without prior flaviviral immunological experience resulted in monotypic YF HI and/or N antibody seroconversions, but no CF antibody response. The presence of prevaccination YF N antibodies blocked serological response to the vaccine in a high proportion of the cases; however, 24% of vaccinees in this group had a marked rise in log2 YF CF antibody titer (mean increase of 3.9). Thirteen (46%) of 28 persons without prevaccination YF N, but with heterologous flaviviral HI antibodies demonstrated YF CF antibody seroconversion or increase in titer following vaccination; in this group the mean increase in log2/ YF CF antibody titer was 2.1. The CF antibody response was generally broadly cross-reactive; but in a few individuals, the YF CF antibody response was homotypic. Nine different patterns of HI and CF homologous and heterologous antibody responses were defined and are discussed. The practical significance of these studies is that they demonstrate that in a high percentage of persons with prior flavivirus exposure, anamnestic serological responses to YF vaccine result in CF antibodies similar to those induced by natural YF virus infection. In Africa and tropical America, where the background of flaviviral immunity is high, it is imperative that seroepidemiologic investigations during or after YF outbreaks be conducted prior to vaccination.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7406113     DOI: 10.4269/ajtmh.1980.29.624

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

Review 1.  Zika Virus Emergence and Expansion: Lessons Learned from Dengue and Chikungunya May Not Provide All the Answers.

Authors:  Rebecca C Christofferson
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

2.  Zika Virus (ZIKV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-10-14       Impact factor: 3.747

3.  Household-based sero-epidemiologic survey after a yellow fever epidemic, Sudan, 2005.

Authors:  Eileen C Farnon; L Hannah Gould; Kevin S Griffith; Magdi S Osman; Amgad El Kholy; Maria-Emanuela Brair; Amanda J Panella; Olga Kosoy; Janeen J Laven; Marvin S Godsey; William Perea; Edward B Hayes
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

4.  Anamnestic immune response to dengue and decreased severity of yellow Fever.

Authors:  Ricardo O Izurieta; Maurizio Macaluso; Douglas M Watts; Robert B Tesh; Bolivar Guerra; Ligia M Cruz; Sagar Galwankar; Sten H Vermund
Journal:  J Glob Infect Dis       Date:  2009-07

Review 5.  The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact.

Authors:  Phillipe Boeuf; Heidi E Drummer; Jack S Richards; Michelle J L Scoullar; James G Beeson
Journal:  BMC Med       Date:  2016-08-03       Impact factor: 8.775

Review 6.  Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update.

Authors:  Raj K Singh; Kuldeep Dhama; Kumaragurubaran Karthik; Ruchi Tiwari; Rekha Khandia; Ashok Munjal; Hafiz M N Iqbal; Yashpal S Malik; Rubén Bueno-Marí
Journal:  Front Microbiol       Date:  2018-01-19       Impact factor: 5.640

7.  Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus.

Authors:  Eduardo J M Nascimento; Brooke Norwood; Allan Parker; Ralph Braun; Eloi Kpamegan; Hansi J Dean
Journal:  Int J Mol Sci       Date:  2021-11-05       Impact factor: 5.923

Review 8.  Flavivirus NS1 and Its Potential in Vaccine Development.

Authors:  Kassandra L Carpio; Alan D T Barrett
Journal:  Vaccines (Basel)       Date:  2021-06-09

Review 9.  Addressing knowledge gaps in molecular, sero-surveillance and monitoring approaches on Zika epidemics and other arbovirus co-infections: A structured review.

Authors:  Ernest Tambo; Christopher Khayeka-Wandabwa; Oluwasogo A Olalubi; Ahmed A Adedeji; Jeanne Y Ngogang; Emad Im Khater
Journal:  Parasite Epidemiol Control       Date:  2017-02-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.